| [1] |
Heinhuis B, Koenders MI, van Riel PL, et al. Tumour necrosis factor α-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade[J]. Ann Rheum Dis, 2011, 70 (4): 660-667.
|
| [2] |
Meyer N, Zimmermann M, Burgler S, et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis[J]. J Allergy Clin Immunol, 2010, 125 (4): 858-865.
|
| [3] |
Nold-Petry CA, Nold MF, Zepp JA, et al. IL-32-dependent effects of IL-1β on endothelial cell functions[J]. Proc Natl Acad Sci USA, 2009, 106 (10): 3883-3888.
|
| [4] |
Dahl CA, Schall RP, He HL, et al. Identification of a novel gene expressed in activated natural killer cells and T cells[J]. J Immunol, 1992, 148 (2): 597-603.
|
| [5] |
Goda C, Kanaji T, Kanaji S, et al. Involvement of IL-32 in activation-induced cell death in T cells[J]. Int Immunol, 2006, 18 (2): 233-240.
|
| [6] |
Kang JW, Park YS, Lee DH, et al. Interaction net-work mapping among IL-32 isoforms[J]. Biochimie, 2014, 101: 248-251.
|
| [7] |
Kim JD, Kang Y, Kim J, et al. Essential role of Apelin signaling during lymphatic development in zebrafish[J]. Arterioscler Thromb Vasc Biol, 2014, 34 (2): 338-345.
|
| [8] |
Heinhuis B, Koenders MI, van de Loo FA, et al. Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis[J]. Proc Natl Acad Sci USA, 2011, 108 (12): 4962-4967.
|
| [9] |
Schenk M, Krutzik SR, Sieling PA, et al. NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy[J]. Nat Med, 2012, 18 (4): 555-563.
|
| [10] |
Xu Q, Pan X, Shu X, et al. Increased interleukin-32 expression in chronic hepatitis B virus-infected liver[J]. J Infect, 2012, 65 (4): 336-342.
|
| [11] |
Kudo M, Ogawa E, Kinose D, et al. Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells[J]. Respir Res, 2012, 13: 19.
|
| [12] |
Kang YH, Park MY, Yoon DY, et al. Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2[J]. Cancer Lett, 2012, 318 (2): 226-233.
|
| [13] |
Khawar B, Abbasi MH, Sheikh N. A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation[J]. Eur J Med Res, 2015, 20:7.
|
| [14] |
Hong J, Cho IH, Kwak KI, et al. Microglial Toll-like receptor 2 contributes to kainic acid-induced glial activation and hippocampal neuronal cell death[J]. J Biol Chem, 2010, 285 (50): 39447-39457.
|
| [15] |
Kang JW, Park YS, Lee DH, et al. Interaction net-work mapping among IL-32 isoforms[J]. Biochimie, 2014, 101: 248-251.
|
| [16] |
Nishida A, Andoh A, Shioya M, et al. Phosphatidylinositol 3-kinase/Akt signaling mediates inter-leukin-32α induction in human pancreatic periacinar myofibroblasts[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 294 (3): G831-G838.
|
| [17] |
Kobayashi H, Yazlovitskaya EM, Lin PC. Interleukin-32 positively regulates radiation-induced vascular inflammation[J]. Int J Radiat Oncol Biol Phys, 2009, 74 (5): 1573-1579.
|
| [18] |
Kim YG, Lee CK, Oh JS, et al. Effect of interleukin-32γ on differentiation of osteoclasts from CD14+ monocytes[J]. Arthritis Rheum, 2010, 62(2): 515-523.
|
| [19] |
Mun SH, Kim JW, Nah SS, et al. Tumor necrosis factor α-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts[J]. Arthritis Rheum, 2009, 60 (3): 678-685.
|
| [20] |
Lee S, Kim JH, Kim H, et al. Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene[J]. Immunology, 2011, 132 (3): 410-420.
|
| [21] |
Ko NY, Mun SH, Lee SH, et al. Interleukin-32α production is regulated by MyD88-dependent and independent pathways in IL-1β-stimulated human alveolar epithelial cells[J]. Immunobiology, 2011, 216 (1-2): 32-40.
|
| [22] |
Heinhuis B, Koenders MI, van den Berg WB, et al. Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1[J]. J Biol Chem, 2012, 287 (8): 5733-5743.
|
| [23] |
Moschen AR, Fritz T, Clouston AD, et al. Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis[J]. Hepatology, 2011, 53 (6): 1819-1829.
|
| [24] |
Turner-Brannen E, Choi KY, Arsenault R, et al. Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1[J]. J Immunol, 2011, 186 (12): 7127-7135.
|
| [25] |
Mabilleau G, Sabokbar A. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation[J]. PLoS One, 2009, 4 (1): e4173.
|
| [26] |
Oh JH, Cho MC, Kim JH, et al. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals[J]. Oncogene, 2011, 30 (30): 3345-3359.
|
| [27] |
Yun HM, Oh JH, Shim JH, et al. Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals[J]. Cell Death Dis, 2013, 4: e640.
|
| [28] |
Rakoff-Nahoum S, Bousvaros A. Innate and adaptive immune connections in inflammatory bowel diseases[J]. Curr Opin Gastroenterol, 2010, 26 (6): 572-577.
|
| [29] |
Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD)1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism[J]. Proc Natl Acad Sci USA, 2005, 102 (45): 16309-16314.
|
| [30] |
Heinhuis B, Koenders MI, van den Berg WB, et al. Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1[J]. J Biol Chem, 2012, 287 (8): 5733-5743.
|
| [31] |
Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility[J]. Nat Rev Mol Cell Biol, 2005, 6(1): 56-68.
|
| [32] |
Nakayama M, Niki Y, Kawasaki T, et al. IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis[J]. Sci Rep, 2013, 3: 2960.
|
| [33] |
Riise RE, Bernson E, Aurelius J, et al. TLR-stimulated neutrophils instruct NK cells to trigger dendritic cell maturation and promote adaptive T cell responses[J]. J Immunol, 2015, 195 (3): 1121-1128.
|
| [34] |
Hellerud BC, Olstad OK, Nielsen EW, et al. Massive organ inflammation in experimental and in clinical meningococcal septic shock[J]. Shock, 2015, 44 (5): 458-469.
|
| [35] |
Hong J, Bae S, Kang Y, et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta[J]. Cytokine, 2010, 49 (2): 171-176.
|
| [36] |
Kim SJ, Lee S, Kwak A, et al. Interleukin-32γ transgenic mice resist LPS-mediated septic shock[J]. J Microbiol Biotechnol, 2014, 24 (8): 1133-1142.
|
| [37] |
Zepp JA, Nold-Petry CA, Dinarello CA, et al. Protection from RNA and DNA viruses by IL-32[J]. J Immunol, 2011, 186 (7): 4110-4118.
|
| [38] |
Bae S, Kang D, Hong J, et al. Characterizing antiviral mechanism of interleukin-32 and a circulating soluble isoform in viral infection[J]. Cytokine, 2012, 58 (1): 79-86.
|
| [39] |
Osman A, Bhuyan F, Hashimoto M, et al. M-CSF inhibits anti-HIV-1 activity of IL-32, but they enhance M2-like phenotypes of macrophages[J]. J Immunol, 2014, 192 (11): 5083-5089.
|
| [40] |
Smith AJ, Toledo CM, Wietgrefe SW, et al. The immuno-suppressive role of IL-32 in lymphatic tissue during HIV-1 infection[J]. J Immunol, 2011, 186 (11): 6576-6584.
|
| [41] |
Monteleone K, Di Maio P, Cacciotti G, et al. Inter-leukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients[J]. Med Microbiol Immunol, 2014, 203 (3): 207-216.
|
| [42] |
Xu Q, Pan X, Shu X, et al. Increased interleukin-32 expression in chronic hepatitis B virus-infected liver[J]. J Infect, 2012, 65 (4): 336-342.
|
| [43] |
Yang K, Guan SH, Zhang H, et al. Enhanced levels of interleukin-8 are associated with hepatitis B virus infection and resistance to interferon-α therapy[J]. Int J Mol Sci, 2014, 15 (11): 21286-21298.
|
| [44] |
Bai X, Ovrutsky AR, Kartalija M, et al. IL-32 expression in the airway epithelial cells of patients with mycobacterium avium complex lung disease[J]. Int Immunol, 2011, 23 (11): 679-691.
|
| [45] |
Montoya D, Inkeles MS, Liu PT, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis[J]. Sci Transl Med, 2014, 6 (250): 114r-250r.
|
| [46] |
Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity[J]. Ann Rheum Dis, 2010, 69 (11): 1920-1925.
|
| [47] |
Figueroa-Vega N, Moreno-Frias C, Malacara JM. Alterations in adhesion molecules, pro-inflammatory cytokines and cell-derived microparticles contribute to intima-media thickness and symptoms in postmenopausal women[J]. PLoS One, 2015, 10 (5): e120990.
|
| [48] |
Peeters W, Moll FL, Vink A, et al. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome[J]. Eur Heart J, 2011, 32 (18): 2314-2325.
|
| [49] |
Lee YG, Jeong JJ, Nyenhuis S, et al. Recruited alveolar macrophages, in response to airway epithelial-derived monocyte chemoattractant protein 1/CCl2, regulate airway inflammation and remodeling in allergic asthma[J]. Am J Respir Cell Mol Biol, 2015, 52 (6): 772-784.
|
| [50] |
Chen Y, Molnar M, Li L, et al. Characterization of VCAM-1-binding peptide-functionalized quantum dots for molecular imaging of inflamed endothelium[J]. PLoS One, 2013, 8 (12): e83805.
|
| [51] |
Nold-Petry CA, Nold MF, Zepp JA, et al. IL-32-dependent effects of IL-1beta on endothelial cell functions[J]. Proc Natl Acad Sci USA, 2009, 106 (10): 3883-3888.
|
| [52] |
Heinhuis B, Popa CD, van Tits BL, et al. Towards a role of interleukin-32 in atherosclerosis[J]. Cytokine, 2013, 64 (1): 433-440.
|
| [53] |
Heinhuis B, Koenders MI, van Riel PL, et al. Tumor necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade[J]. Ann Rheum Dis, 2011, 70 (4): 660-667.
|
| [54] |
Soyka MB, Treis A, Eiwegger T, et al. Regulation and expression of IL-32 in chronic rhinosinusitis[J]. Allergy, 2012, 67 (6): 790-798.
|
| [55] |
Li D, Chen D, Zhang X, et al. c-Jun N-terminal kinase and Akt signalling pathways regulating tumour necrosis factor-α-induced interleukin-32 expression in human lung fibroblasts: implications in airway inflammation[J]. Immunology, 2015, 144 (2): 282-290.
|
| [56] |
Meyer N, Christoph J, Makrinioti H, et al. Inhibition of angiogenesis by IL-32: possible role in asthma[J]. J Allergy Clin Immunol, 2012, 129 (4): 964-973.
|
| [57] |
Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism[J]. Proc Natl Acad Sci USA, 2005, 102 (45): 16309-16314.
|
| [58] |
Shioya M, Nishida A, Yagi Y, et al. Epithelial over-expression of interleukin-32alpha in inflammatory bowel disease[J]. Clin Exp Immunol, 2007, 149 (3): 480-486.
|
| [59] |
Corfe BM, Majumdar D, Assadsangabi A, et al. Inflammation decreases keratin level in ulcerative colitis; inadequate restoration associates with increased risk of colitis-associated cancer[J]. BMJ Open Gastroenterol, 2015, 2 (1): e24.
|
| [60] |
Ishigami S, Arigami T, Uchikado Y, et al. IL-32 expression is an independent prognostic marker for gastric cancer[J]. Med Oncol, 2013, 30 (2): 472.
|
| [61] |
Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype[J]. Am J Respir Crit Care Med, 2009, 180 (8): 769-779.
|
| [62] |
Ozbek E, Aliskan T, Otunctemur A, et al. Comparison of tumor grade and stage with nuclear factor κ b and p38 mitogene activated protein kinase expressions in renal cell cancer[J]. Arch Ital Urol Androl, 2012, 84 (2): 53-60.
|
| [63] |
Yousif NG, Al-Amran FG, Hadi N, et al. Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer[J]. Cytokine, 2013, 61 (1): 223-227.
|
| [64] |
Park MH, Song MJ, Cho MC, et al. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3[J]. Immunology, 2012, 135 (1): 63-72.
|
| [65] |
Lee NJ, Choi DY, Song JK, et al. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model[J]. Carcinogenesis, 2012, 33 (12): 2520-2528.
|
| [66] |
Yun HM, Oh JH, Shim JH, et al. Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals[J]. Cell Death Dis, 2013, 4: e640.
|
| [67] |
Ferlay J, Shin HR, Bray F, et al. Estimates of world-wide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127 (12): 2893-2917.
|
| [68] |
Lv Q, Sun H, Cao C, et al. Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1) are associated with poor prognosis of epithelial ovarian cancer[J]. Tumour Biol, 2015, Sep 25. [Epub ahead of print].
|
| [69] |
Chang F, Lacey MR, Bouljihad M, et al. Tumor necrosis factor receptor 1 functions as a tumor suppressor[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302 (2): G195-G206.
|
| [70] |
Becker D, Deller T, Vlachos A. Tumor necrosis factor (TNF)-receptor 1 and 2 mediate homeostatic synaptic plasticity of denervated mouse dentate granule cells[J]. Sci Rep, 2015, 5: 12726.
|
| [71] |
Yun HM, Park KR, Kim EC, et al. IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling[J]. Oncotarget, 2015, 6 (11): 9061-9072.
|